Asthma

Atrial Fibrillation

Autoimmune Diseases

Biologics

Biosimilars

Blood Cancer

Breast Cancer

COVID-19

Cardiovascular Diseases

Depression

Dermatology

Diabetes

Digital Health

Drug Coverage

Eyecare

Friedreich Ataxia

Gene Therapy

Graft Versus Host Disease

Heart Failure

Hemophilia

Hypertrophic Cardiomyopathy (HCM)

Leukemia and Lymphoma

Liver Disease

Lung Cancer

Mental Health

Multiple Sclerosis

NSCLC

Neonatal Care

Obstetrics-Gynecology & Women's Health

Oncology

Opioids

PTSD

Pain

Pediatrics

Plaque Psoriasis

Population Health

Post-Acute Care

Prescription Digital Therapeutics

Pulmonary Arterial Hypertension

Reproductive Health

Respiratory Conditions

Safety & Recalls

Skin Cancer

Sleep Disorders

Solid Tumors

Spinal Muscular Atrophy

Substance Use Disorder

The Improving Patient Access Podcast

Type I Diabetes

Type II Inflammation

Ulcerative Colitis

Urology

Urothelial Carcinoma

Vaccines

Vaccines: 2023 Year in Review

Women's Health

News

Media

Between the Lines

Expert Interviews

K-Cast

Medical World News

Podcasts

Population Health Perspectives

Conferences

Partners

Publications

All Publications

MHE Publication

Formulary Watch Supplements

Formulary Watch Spotlights

Supplements And Featured Publications

Events

2024 PBMI Annual National Conference

PBMI MAP

Virtual Events

CME/CE

Resources

Emerging Leaders

Interactive Tools

PBM Leaders

Subscribe

Articles

The FDA has approved UCB's Bimzelx for moderate-to-severe hidradenitis suppurativa, offering a new treatment option for this painful autoimmune skin disease.

FDA Approves Bimzelx for Inflammatory Skin Disease

Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.

Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI

Medicare fraud costs Americans about $60 billion each year and healthcare plans are stepping in spread awareness and stop criminals. 

Medicare Open Enrollment Attracts Enrollees and Scammers Alike

Peter Wehrwein has been the lead editor of Managed Healthcare Executive since February 2020.

Mehmet Oz, M.D., is another unconventional pick by Trump and is perhaps another an indication that Trump intends to let his HHS secretary nominee, Robert F. Kennedy Jr., "go wild on health."  

Trump Picks Oz for CMS Administrator

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, insights, and strategies to pursue value-driven solutions.

About Us

Advertise

Editorial

Contact Us

Terms and Conditions

Privacy

Do Not Sell My Personal Information

Managed Healthcare Executive

Facebook

LinkedIn

Resource Centers

Eye Care

Spotlight

ID Week 2024

AMCP Nexus 2024

AHIP

AIDS Conference

ATS 

Business

Business Strategy

Chronic Disease

Consumers

Drug Costs

Drug Pipeline

Formulary

Health Management

Health/Disease Strategy

Hospitals & Providers

Industry Analysis

Pharmacy

Politics and Policy

Practice Management

Reimbursement

Technology

1rem

Continuing Medical Education

42nd Annual CFS: Innovative Cancer Therapy for Tomorrow®

19th Annual New York Lung Cancers Symposium®

Andre H. Goy, MD; Sandra M. Swain, MD, FACP, FASCO Associate Dean for Research; Carolina Bernabe Ramirez, MD; Jonathan E. Rosenberg, MD; David H. Vesole, MD, PhD, FACP Director, Myeloma Program; Isabel Preeshagul, DO, MBS  
 

Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board

Lynette M. Sholl, MD; Jason Chang, MD; Sonam Puri, MD 

Identifying Actionable Biomarkers in NSCLC: Real World Case Discussions on Applications of Testing in the Treatment Planning Process

David Planchard, MD, PhD; Martin F. Dietrich, MD, PhD

How CEACAM5 Expression Can Be Measured and Leveraged in NSCLC Care: Current Developments & Future Therapeutic Opportunities

Benjamin P. Levy, MD; Komal Jhaveri, MD, FACP; Joshua K. Sabari, MD

Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!

David Carbone, MD, PhD; Neel P. Chudgar, MD; Daniel Gomez, MD, MBA; Jianjun Zhang, MD, PhD

Lung Cancer Tumor Board®: Enhancing Multidisciplinary Communication to Optimize Immunotherapy in Stage I-III NSCLC

Lyudmila A. Bazhenova, MD; Julia Rotow, MD; Catherine A. Shu, MD

Matching Treatment to Patient with EGFR-Mutant Lung Cancer: Mutation Subtypes, Co-Mutations, and Managing Resistance

Improving Outcomes Across Frontline and R/R SCLC Care in Community Treatment Settings

Annual Hawaii Cancer Conference

Benjamin P. Levy, MD; John O. Mascarenhas, MD; Alison J. Moskowitz, MD; Diane Reidy-Lagunes, MD; Tiffany A. Traina, MD, FASCO; David R. Wise, MD, PhD

 41st Annual CFS®: Innovative Cancer Therapy for Tomorrow

Balazs Halmos, MD, MS; Mark G. Kris, MD; Jamie E. Chaft, MD; Stephen V. Liu, MD


18th Annual New York Lung Cancers Symposium®

22nd Annual Winter Lung Cancer Conference®

Brendon M. Stiles, MD; Jamie E. Chaft, MD; Balazs Halmos, MD, MS

 Dialogues With the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: Looking at EGFR, ALK, IO, and Beyond…

Benjamin Levy, MD; Christine M. Lovly, MD, PhD

21st Annual Winter Lung Cancer Conference® In Line Session: Advent of TROP2-Directed ADCs In Lung Cancer

Ignacio I. Wistuba, MD; Charu Aggarwal, MD, MPH; Justin Gainor, MD; Lynette Sholl, MD

LIVE! Testing Board®: Breaking Down Pathologic Reports to Identify Actionable Markers in Patients with NSCLC

Benjamin P. Levy, MD; Ignacio I. Wistuba, MD; Lynette M. Sholl, MD; Kristen A. Marrone, MD;

Tissue Stewardship and the Evolving Role of Genomic Alterations in Providing Precision NSCLC Care

Julie R. Brahmer, MD, MSc, FASCO; Bruna Pellini, MD; Jaime Laurel Schneider, MD, PhD; Mark A. Socinski, MD

Community Practice Connection™: 21st Annual Winter Lung Cancer Conference®

Melissa Johnson, MD; Edward Garon, MD, MS; Solange Peters, MD, PhD; Ignacio I. Wistuba, MD

Revolutionizing Early-Stage NSCLC Treatment: Pathologists’ Key Insights Into Predicting Pathologic Responses to Immunotherapies

BURST CME™: How Are Emerging Biomarkers and Testing Methodologies Shaping Personalized Medicine in NSCLC?

Stephen V. Liu, MD; Benjamin P. Levy, MD, FASCO; Laura Macke, MS, BSN, FNP-C, AOCNP; Michelle M. Turner, MSN, CRNP

Navigating Current State-of-the Art NSCLC Patient Care From the Front Lines: Essentials for Oncology Nurses Today and Tomorrow

Edward S. Kim, MD, MBA; Leah M. Backhus MD, MPH, FACS; Lyudmila A. Bazhenova, MD

Medical Crossfire®: How Can Thoracic Teams Facilitate Optimized Care of Patients With Stage I-III EGFR Mutation-Positive NSCLC?

Anne Chiang, MD, PhD; Megan E. Daly, MD; Carl M. Gay, MD, PhD; Jacob Sands, MD

Lung Cancer Tumor Board®: How Do Emerging Data for ICIs, BiTEs, ADCs, and Targeted Strategies Address Unmet Needs in the Therapeutic Continuum for SCLC?

Ticiana Leal, MD; Jennifer W. Carlisle, MD; Nisha Mohindra, MD; Martin Wermke, MD

DLL3 as a Therapeutic Target in SCLC and Beyond: Rationale, Recent Data and Potential for Transformations in Care with T-Cell Engagers

Karen M. Winkfield, MD, PhD; Narjust Florez, MD, FASCO; Gilberto de Lima Lopes Junior, MD, MBA, FASCO; Coral Olazagasti, MD; Vonetta M. Williams, MD, PhD

 Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care

Melissa Johnson, MD; Dara Aisner, MD, PhD; David R. Gandara, MD; Balazs Halmos, MD, MS

Top 10 Oncogenic Drivers in NSCLC for 2024: Where Are We and Where Are We Going?

26th Annual International Lung Cancer Congress®

Advances In™: Moving Care Forward in SCLC with DLL3 Targeting Bispecific T-Cell Engagers

Jeneth Aquino, DNP, FNP-BC; Beth Sandy, MSN, CRNP, FAPO; Allison M. Walker, ACNP, MSN, MSW, BS

Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management

Jacob Sands, MD; Myung-Ju Ahn, MD; Aaron Lisberg, MD

What’s Next for HER2- and TROP2-Directed ADCs in Lung Cancer: How Emerging Trial Data will Impact our Clinics Today, and Tomorrow….

Anne Chiang, MD, PhD; Jonathan Wesley Riess, MD, MS; Misty D. Shields, MD, PhD

Do We Have Sea Change in Small Cell Lung Cancer? What Recent Clinical Trial Data Tell Us About Treatment Decision-Making in Real-World Settings, What’s Next for Emerging Novel Strategies

David R. Gandara, MD; Roy S. Herbst, MD, PhD; Pasi Jänne, MD, PhD; Heather A. Wakelee, MD, FASCO

Community Practice Connections™: 25th Annual International Lung Cancer Congress

Beth Sandy, MSN, CRNP, FAPO; Laura Wood, RN, MSN, OCN; Michael Lai, ARNP; Tiffany Richards, PhD, ANP-BC, AOCNP®; Lauren Verity Moore, DNP, MSN, AGACNP-BC; Megan Wanca, APRN, DNP, FNP-C

Community Practice Connections™: 8th Annual School of Nursing Oncology™

Charu Aggarwal, MD, MPH, FASCO; Christine Bestvina, MD; Hatim Husain, MD; Karen L. Reckamp, MD, MS

Lung Cancer Tumor Board: Enhancing Precision Medicine in NSCLC Through Advancements in Molecular Testing and Optimal Therapy Selection

Megan E. Daly, MD; Nagla F. Abdel Karim, MD, PhD; Chul Kim, MD

(CME Credit Only) New Frontiers in Immunotherapy for SCLC: Insights From Latest Clinical Trials and Their Application in Real-World Treatment

(MOC and CME Credit) New Frontiers in Immunotherapy for SCLC: Insights From Latest Clinical Trials and Their Application in Real-World Treatment

Percy Lee, MD, FASTRO; David Harpole Jr, MD; Julia Rotow, MD

(CME Credit Only) Lung Cancer Tumor Board®: The Pivotal Role of Multimodal Therapy in Leveraging Immunotherapy for Stage I-III NSCLC When the Goal Is Cure

(MOC and CME Credit) Lung Cancer Tumor Board®: The Pivotal Role of Multimodal Therapy in Leveraging Immunotherapy for Stage I-III NSCLC When the Goal Is Cure

Upcoming CME Events & Activities

EVENTS

ACTIVITIES